ZHEJIANG MEDICINES & HEALTH PRODUCTS IMP/EXP CO., LTD.

Introduction

ZHEJIANG MEDICINES & HEALTH PRODUCTS IMP/EXP CO., LTD. (浙江省医药保健品进出口有限责任公司, commonly abbreviated ZMC) is a Hangzhou-based Chinese foreign-trade company founded in 1984 and active in the international trade of pharmaceuticals, medical devices, traditional Chinese medicines, nutritional and health products, and fine chemicals. The company is a provincial-level, state-owned or state-controlled enterprise within Zhejiang’s broader state-owned trade system, and it serves as an export-and-import intermediary linking Chinese manufacturers with overseas distributors and buyers across more than 140 countries and regions.

Within the plastics industry ecosystem, ZMC is relevant primarily through its trade in medical consumables, medical supplies, packaging- and processing-related materials, and chemical inputs that intersect with plastics-based healthcare and industrial supply chains. Public business descriptions indicate that its portfolio includes medical instruments, disposable medical items, rubber and latex products, and related industrial products, positioning the company more as a diversified international trader than as a plastics converter or polymer producer.

History and Development

ZMC’s corporate history is generally traced to the mid-1980s, with company materials describing its founding in 1984 and later restructuring into its present foreign-trade form in 1999. Its development reflects the broader evolution of Zhejiang’s export-oriented manufacturing economy, in which trading firms aggregate products from a large base of domestic suppliers for overseas markets.

Several milestones stand out:

• The company built a broad supplier network, reporting cooperation with about 2,000 domestic suppliers, including 138 pharmaceutical and chemical enterprises in Zhejiang Province.
• It expanded into a wide export footprint, with products sold to more than 140 countries and regions and a customer base of roughly 2,000 foreign clients.
• Industry-facing materials indicate repeated recognition by the China Chamber of Commerce for Import and Export of Medicines and Health Products, including strong rankings among exporters of Chinese and Western medicines and pharmaceutical raw materials.

Publicly available profiles also indicate that ZMC participated in major industry exhibitions and was recognized for long-running presence in the pharmaceutical trade exhibition ecosystem, underscoring its established position in China’s cross-border health-products trade.

Business Operations and Segments

ZMC operates as a professional foreign trade company rather than as a pure manufacturer. Its business model is centered on sourcing, trade coordination, export, import, and distribution across multiple health-related product categories.

The company’s reported business scope includes:

• Pharmaceuticals
• Medical devices and medical consumables
• Traditional Chinese medicine products
• Nutritional and health products
• Fine chemicals

A university recruitment profile describes an even broader product and trade mix, including pharmaceutical intermediates and formulations, biologics, medical dressings, one-time-use medical products, as well as some general industrial goods such as textiles and light industrial products. This breadth suggests that ZMC functions as an integrated trading platform connecting upstream producers to export markets rather than as a vertically integrated industrial manufacturer.

Products and Technologies

ZMC’s product portfolio spans several technically distinct categories.

Publicly accessible industry listings also associate the company with medical instruments, needles and syringes, surgical dressings, diagnostic instruments, rubber and latex products, and packaging materials used in pharmaceutical trade. In practical terms, these categories place ZMC near several plastics-intensive value chains, especially in disposable healthcare products, sterile packaging, protective materials, and device components.

Although the company is not presented as a polymer producer or plastics processor, its trade activity intersects with plastics through:

• Disposable medical consumables, which commonly use polypropylene, polyethylene, PVC, or related medical-grade polymers.
• Medical device packaging, which relies on barrier films, trays, blisters, and sterile packaging systems.
• Chemical intermediates and fine chemicals, which may feed into polymer-adjacent industrial supply chains.

Applications and End Markets

ZMC serves a diversified set of end markets tied to healthcare, life sciences, and industrial chemistry.

Major applications include:

• Pharmaceutical manufacturing and distribution
• Hospital and clinical supply chains
• Consumer health and wellness
• Agricultural and agrochemical distribution
• Industrial chemistry and specialty chemical trade
• Medical consumables and disposable healthcare products

The company’s trade profile indicates particularly strong exposure to international pharmaceutical and health-product markets, while its agrochemical and fine-chemical activities connect it to the broader specialty chemicals sector. This diversification can reduce dependence on a single product class, but it also requires compliance with a wide array of standards covering pharmaceuticals, medical devices, food-related products, and chemical trade.

Global Presence and Market Position

ZMC reports sales to customers in more than 140 countries and regions, with India identified in company materials as its largest export market. It also maintains long-term relationships with nearly 2,000 overseas customers, indicating a sizable and enduring international trading network.

The company’s market position is best understood in terms of trade intermediation and category breadth rather than large-scale manufacturing. Industry directories and exhibition profiles describe it as a major Chinese exporter in medicines, medical products, and related chemicals, with strong visibility in international trade fairs and business platforms. Some third-party listings further associate ZMC with exports of agrochemicals and pharmaceutical preparations, suggesting a multi-segment trade footprint.

Sustainability and Environmental Initiatives

Publicly available company materials do not provide a detailed sustainability report or quantified environmental targets in the sources reviewed. However, ZMC’s business mix touches product categories that are heavily affected by environmental and regulatory scrutiny, particularly medical disposables, chemical trade, and packaging-related materials.

From an industry perspective, the company’s environmental profile is likely shaped by:

• Compliance requirements in cross-border chemical and pharmaceutical trade
• Increasing demand for traceability in health-related supply chains
• Packaging and waste-management pressures associated with disposable medical goods

Because the company is primarily a trader, many direct environmental impacts would typically arise upstream at manufacturing partners and downstream in logistics and product use rather than inside a large-scale conversion facility.

Financial Performance and Economic Impact

The sources reviewed do not provide a recent audited revenue figure in company materials, but third-party business databases describe ZMC as a substantial enterprise with a large workforce and significant export activity. One profile reported registered capital of RMB 80 million, total assets of RMB 1.08 billion, and net assets of RMB 287 million as of 2012.

ZMC’s economic role is notable in Zhejiang’s export economy because it aggregates demand from overseas buyers and channels orders to a broad domestic supplier base. Its activities support:

• Export sales for pharmaceutical and chemical manufacturers
• Access to global markets for medium-sized Chinese producers
• Trade logistics and compliance functions in regulated health-related categories

Leadership and Corporate Governance

ZMC is described as a provincial state-owned professional foreign-trade enterprise affiliated with Zhejiang’s state-owned business groups. Company and related institutional materials indicate that it sits within a state-owned governance structure connected to Zhejiang International Business Group and the province’s broader state-owned assets system.

Public sources also identify a legal representative and various executive contacts, but the reviewed materials do not provide a current full board or senior-management roster in a unified official filing. The company’s participation in industry associations suggests governance aligned with China’s regulated pharmaceutical and health-products trade environment.

Innovations and Future Outlook

ZMC’s innovation profile is more commercial and logistical than manufacturing-technical. Its business development appears focused on expanding product breadth, maintaining supplier relationships, and managing compliance across complex international trade channels.

Future opportunities and pressures are likely to come from:

• Higher compliance standards in pharmaceuticals and medical devices
• Greater demand for traceable and quality-assured supply chains
• Ongoing diversification in health products, fine chemicals, and medical consumables
• Continued competition in Asia-linked export markets, especially in pharmaceuticals and agrochemicals

For the plastics sector specifically, ZMC’s relevance is likely to remain tied to medical disposables, device-related materials, and packaging-adjacent supply chains, rather than to resin production or plastics processing itself.

References

• •

  CPS+ eMarketplace. (n.d.). ZHEJIANG MEDICINES & HEALTH PRODUCTS IMP/EXP CO., LTD.ZHEJIANG MEDICINES & HEALTH PRODUCTS IMP/EXP CO., LTD.. CPS+ eMarketplace. https://www.chinaplasonline.com/eMarketplace/ExhibitorInfo?CompId=1017288Link